Navigation Links
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Date:3/31/2008

participation in IDENTITY. Because the IDENTITY study also incorporates a "randomized delayed start" design, even those subjects initially assigned to the placebo arm of the study will be started on active LY450139 treatment sometime before the end of the 21-month study period. Both the subjects and investigators will be blinded to the exact timing of this delayed start of study drug administration.

"Alzheimer's is a devastating disease that destroys brain cells, affecting everything from a patient's memory to their work and social life. Currently available medications treat the symptoms of Alzheimer's disease but have not been shown to change its underlying progression, creating an urgent unmet medical need. Today, we are proud to announce the start of the IDENTITY clinical trial and hold hope that LY450139 will represent an advance in the attempt to slow the progression of this fatal disease. We encourage patients or their caregivers to review the enrollment criteria for IDENTITY to see if they are eligible to participate," said Eric Siemers M.D., Medical Director, Alzheimer's disease research for Eli Lilly and Company.

Alzheimer's disease is a progressive neurodegenerative condition that is the most common cause of dementia in patients over 65 years of age. Estimates show that 6-8% of people over age 65 are affected by Alzheimer's disease(1), totaling approximately 5 million people in the United States alone(2). Every 72 seconds, an American is developing Alzheimer's disease(3), and it is the seventh-leading cause of death in the United States(4). The direct and indirect health care costs associated with Alzheimer's disease in the U.S. are estimated to be about $150 billion(5). In 2005, the total cost worldwide was estimated at $315.4 billion(6).

Given the aging population, without the availability of medicines that delay or prevent the onset of Alzheimer's disease, the number of affected people is expected to at least triple by the year 2050
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
2. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
3. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
4. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
5. Lilly Receives NCQA Design Certification for Depression Care Management Program
6. Lilly and Glenmark Pharmaceuticals Announce License Agreement
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
9. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
10. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
11. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Legislation backed by the drugstore ... Pharmacies Act of 2014") championing so-called "any willing ... the availability of lower cost preferred pharmacy networks ... the next 10 years, according to new research ... Care Management Association (PCMA). The drugstore ...
(Date:7/22/2014)... , July 22, 2014  Eyeon Therapeutics has received ... treatment based on a charged hydrophilic polymer developed at ... has been shown to be safe and effective in ... MD, CEO states, "This first set of claims around ... way to moving this technology into the commercial phase.  ...
(Date:7/22/2014)... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and ... lots of Fluzone ® (Influenza Vaccine) for the 2014-2015 ... Food and Drug Administration (FDA) for distribution. The lots were ... least 65 million doses of seasonal influenza vaccine manufactured by ... providers and pharmacies in August. The U.S. ...
Breaking Medicine Technology:New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7
... Aug. 17 The hospital patient room of the future ... New Jersey, providing lessons that stand to benefit hospitals and ... building a new hospital in Plainsboro, NJ, to replace its ... a fully functioning replica of the new hospital,s proposed patient ...
... Inc. (NYSE Amex: ULU ) today announced its financial ... the second quarter of 2010, the Company reported a net loss of ... $2.9 million, or $0.04 per share, for the same period last year. ... net loss of $3.5 million, or $0.04 per share, compared with a ...
Cached Medicine Technology:Hospital Room of the Future Debuts in New Jersey 2Hospital Room of the Future Debuts in New Jersey 3Hospital Room of the Future Debuts in New Jersey 4ULURU Inc. Reports Second Quarter 2010 Financial Results 2ULURU Inc. Reports Second Quarter 2010 Financial Results 3ULURU Inc. Reports Second Quarter 2010 Financial Results 4ULURU Inc. Reports Second Quarter 2010 Financial Results 5ULURU Inc. Reports Second Quarter 2010 Financial Results 6
(Date:7/22/2014)... Dr. Dental is excited to announce the ... visitors in mind, one of the main differences from the ... makes navigation very easy. Dr. Dental is renowned for having ... the dentist affordable, convenient and fun, and the new website ... an appointment scheduling system right on the home page where ...
(Date:7/22/2014)... 22, 2014 The 2014 Warrior-Family ... Ronald Reagan Building and International Trade Center in ... Families and Civilian Communities,” will be held from ... 7:30 a.m.) and cohosted by the Military Officers ... Industrial Association (NDIA). USAA is the Executive Sponsor ...
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will serve ... for the 2014-2015 fiscal year. He joined the Board ... "“Serving on the HASA board has given me a broader, ... remember how much others need help." , ABOUT AARON MARSHALL:, ... a B.S. in Finance from the University of Delaware. Currently, ...
(Date:7/22/2014)... Steven Reinberg HealthDay ... Two treatments that break up blood clots deep in the ... death risk. However, one results in a greater risk of ... cost of the other treatment, a new study finds. ... vein thrombosis (DVT) -- is blood-thinning medications and compression stockings. ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor ... Los Angeles with the 2014 E. Donnall Thomas ... the discovery of the iron-regulatory hormone hepcidin and investigation ... after the Nobel Prize Laureate and past Society president ... hematology that have represented a paradigm shift or significant ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:New Board President for Baltimore-based Nonprofit 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3
... at Telemedicine Conference in Las Vegas, Booth 1206 LAS ... Suisse AG (Fora Care,s Swiss sister company) announced today ... American Telemedicine Association (ATA) conference through April 28 at ... The veteran telemedicine companies are presenting at the ...
... following is being issued by American Stroke Association: , , ... It,s better to find out than miss out. Be aware ... and their side effects. Ask if your home should be modified ... doctor, nurse or therapist to clarify any unanswered questions or to ...
... Daily exposure to toxins in the products we ... insecticides, are creating a toxic load on our bodies ... In light of increased awareness of our environmental exposures, ... ) announced today the release of three new testing ...
... campaign reflects diverse communities; focuses on health advocacy ... Kaiser Permanente is adding two new television commercials ... campaign this month. The 30-second ads, titled "Mural" ... communities it serves, as well as the organization,s ...
... painful flare-ups, study finds , , MONDAY, April 27 (HealthDay ... and inexpensive way of treating children with eczema, according ... 17 percent of school-age children, can affect youngsters, appearance, ... , Eczema-related itching can be so bad that children ...
... have a ,baseline, prostate cancer screen at 40, but yearly ... 27 (HealthDay News) -- New guidelines on prostate cancer screening ... for many men, but the same guidelines call for a ... 50. , A prostate-specific antigen (PSA) test to detect early ...
Cached Medicine News:Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 2Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 3Health News:15 Tips Caregivers Should Know After a Loved One Has Had a Stroke 2Health News:15 Tips Caregivers Should Know After a Loved One Has Had a Stroke 3Health News:Metametrix Announces New Toxic Effects Profiles to Help Combat Growing Concerns About Toxicity and Health 2Health News:Kaiser Permanente Continues to Spread Health With New Ads Debuting in April 2Health News:Kaiser Permanente Continues to Spread Health With New Ads Debuting in April 3Health News:Diluted Bleach Baths Ease Kids' Eczema 2Health News:Experts Back Away From Annual PSA Test 2Health News:Experts Back Away From Annual PSA Test 3
... matrix constructed of cross-linked collagen fibers ... through a proprietary 360 accretion process. ... aspirate, Healos provides an excellent environment ... differentiation. The hydroxyapatite-coated collagen microfibers in ...
Sharp Weitlaner Retractor....
Weitlaner retractor, blunt....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
Medicine Products: